Le Lézard
Classified in: Health, Business
Subjects: TNM, CXP

LeapFrog Acquires Majority Stake in Ascent Meditech, a Leading Indian Medical Products Company


LONDON, July 17, 2018 /PRNewswire/ --

Investment will tap into the rapidly growing $100 billion Indian healthcare market and expand the company's export footprint 

LeapFrog Investments ("LeapFrog"), the leading investor in companies that deliver healthcare and financial services for emerging consumers, has acquired a majority stake in Ascent Meditech ("Ascent"), the health company behind the market-leading Flamingo brand. The company's products are currently sold to seven million customers, with a focus on providing high quality and competitively priced orthopaedics to India's aging population.

     (Logo: https://mma.prnewswire.com/media/706245/LeapFrog_Investments_Logo.jpg )

Ascent, which has built a sophisticated manufacturing, distribution and retail strategy, specialises in wound care, mobility aids and orthopaedic soft goods. The company sold 15 million products in 2017 through its extensive network of 150,000 retail pharmacy points across 12 Indian States. Ascent's flagship brand of products, Flamingo, is sold in more than 44 countries across the globe.

Over 80% of Ascent products are for treatment for orthopaedic disorders, which affect over 200 million people in India. The share of India's population over the age of 60 is projected to increase from 8% today to 19% by 2050[3]. Elderly populations tend to have a higher prevalence of orthopaedic ailments, preferring less invasive solutions to surgery.

Felix Olale, Partner and Global Co-Lead for Health Investments at LeapFrog, commented: "The Ascent Meditech team has achieved outstanding growth in the orthopaedic and wound care market, addressing a core need for consumers with high quality products and competitive prices, thus opening up accessibility. We see a huge opportunity for LeapFrog to partner with an outstanding management team to increase production and distribution of Ascent's quality and trusted products, including the flagship Flamingo brand, in India, Asia, Africa, and the Middle East."

The investment in Ascent will capitalise on the favourable dynamics in both the domestic and international markets. The $100 billion Indian healthcare market is expected to expand at 12-15% CAGR. Outside of India, the global market for orthopaedics and prosthetics spend is expected to reach $806.7m by 2020, more than double that of 2014, according to a report by Deloitte[4].

LeapFrog will leverage its deep expertise in healthcare and emerging consumer insights to support Ascent's growth plans and will create additional value through continuing to strengthen the Flamingo brand. This will be achieved by utilising LeapFrog-generated consumer insights to develop additional consumer-focused products, while also expanding Ascent's presence in sub-Saharan Africa and Southeast Asia by leveraging LeapFrog's network in these geographies.

Rajiv Mistry, CEO at Ascent Meditech, commented: "We are delighted to partner with LeapFrog Investments, who share our vision of opening up access to quality and affordable healthcare products and continuing to grow this market leading and trusted brand. Ascent Meditech will benefit greatly from LeapFrog's extensive network, as the company enters its next phase of growth."

This investment builds on LeapFrog's track record in the Indian market and on LeapFrog's decade of experience in partnering with emerging market businesses to provide health insurance to emerging consumers. The company has successfully conducted six full and partial exits from key Indian brands including Mahindra Insurance Brokers, Magma Fincorp, and Northern Arc (formerly IFMR Capital) over the last 19 months. Health exits include global mobile health insurance provider BIMA to Allianz X, and West African life and health insurance provider Express Life, to Prudential PLC.

About LeapFrog Investments 

LeapFrog invests in extraordinary businesses in Africa and Asia. LeapFrog invests in extraordinary businesses in Africa and Asia. We partner with their leaders to achieve leaps of growth, profitability and impact. LeapFrog companies now operate across 149 markets reaching 130 million people with healthcare and financial services. Over 110 million of those are emerging consumers, often accessing insurance, savings, pensions, credit and healthcare for the first time. LeapFrog companies provide jobs and livelihoods to 120,000 people. These companies have grown on average by nearly 40 per cent per annum since LeapFrog's investment. LeapFrog was recently named by Fortune as one of the top five companies changing the world, alongside Apple and Novartis, becoming the first private equity firm ever to be listed.

About Ascent Meditech 

Ascent is a leading consumer healthcare products business in India, underpinned by a 30-year old brand ('Flamingo') and a wide distribution network. The Company was founded in 1991 by Rajiv Mistry who continues to lead the business as CEO. Ascent is a leader in orthopaedic soft goods, wound care and other healthcare products. The Company sold c.15 million products in FY17, with its products being sold via stockists to over 150,000 retail pharmacies in India.

Ascent's flagship brand of products - "FLAMINGO" - sells in more than 40 countries across the globe, primarily in the Middle East, Africa, and Southeast Asia.

Notes:

[1]India Hospital Sector Report - Frost and Sullivan (2017)

[2] World in 2050, PwC (2015); McKinsey (2016)

[3]UNFPA Report - Caring for Our Elders: Early Responses (2017)

[4]Deloitte report - Medical Devices Making in India - A Leap for Indian Healthcare (March 2016)

For further information, please contact:
Greenbrook Communications    
James Madsen / Gina Bell / Ed Jenkins
+44(0)2079522000
[email protected]



These press releases may also interest you

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...



News published on and distributed by: